Q2 2024

After years of innovative engineering, patents and market development, LuminusMicro is now prepared to launch a series of powerful new microsurgical devices. LuminusMicro devices are proven to give surgeons access to key anatomy never seen outside of an operating room, where they achieve unmatched diagnostic accuracy and are also able to deliver treatments with new safety, speed and precision.

Meeting the highest standard for contamination and infection risks, LuminusMicro devices are 100% sterile (disposable – never needing to be cleaned for reuse on another patient). The operating system is portable and nearly free to adopt, offering immediate benefits for all participants in healthcare. Many top surgeons agree that Luminus devices are equipped to bring today’s minimally invasive surgeries into the next era of micro-procedures.

BUSINESS STRATEGY

Considering the micro-size and new capabilities that LuminusMicro devices offer, our surgeon advisors have identified a series of high-volume, high-impact procedure opportunities in every surgical market. Management plans to build a microsurgical brand to deliver breakthroughs into each space, with keen focus on ENT and the Ortho-Spine spaces. Overall, the Luminus business opportunity exceeds a billion US dollars in each surgical market (the long-term portfolio includes 12 potential microsurgical device brands).

TEAM & ASSETS

The Luminus executive team brings together an impressive list of successes where they helped to create and commercialize market-changing, global products that each generated over a $1Billion in sales. Examples include Apple Computers, 3D printing, Arthroscopic Surgery, and several pharmaceutical products. To carry out training and sales, a national distribution network also stands ready.

NEXT STEPS

With Luminus Gen-1 (“X1”) products refined for volume production, management received favorable bids from (5) top US manufacturers to scale up production and complete FDA clearance. Recent reports confirm that Luminus devices are Class II endoscopes – the fastest devices at gaining FDA clearance – often in less than 35 days once production, case impacts and training protocols are documented.

NEW CAPITAL / LIMITED SHAREHOLDER OPPORTUNITY

Multiple healthcare securities firms have agreed on favorable terms and budgets to capitalize the first Luminus product launch. This budget completes key milestones including the 510(k) certification, extinguishing debt, and engaging first live human case use with advising surgeons in key regions. From there sales, operations and engineering staff will expand to support a national sales expansion.

Factors in the firm’s decision to engage Luminus Holdings included the following achievements of management, despite pandemic-related challenges:

● Advancing engineering/pre-production to the manufacture stage
● Validation of demand for the products and straightforward FDA paths
● Expansion of the executive and sales teams, and intellectual property assets
● Expansion of financial resources who intend to invest at specific milestones

Q3 2022

Our engineering team’s continuous innovations have led to significant breakthroughs and extensive new patent opportunities. These breakthroughs are not just incremental improvements; they represent a quantum leap forward in our device designs.

Remarkable reductions in the number of components and layers used in each device enable physically smaller and less expensive devices that can substantially increase profit margins. Moreover, these advancements unlock new opportunities in medical procedures by enabling our devices to reach previously inaccessible anatomical areas.

Furthermore, these enhancements will fortify the physical and mechanical strength of our devices. This translates into products that are more robust, particularly beneficial for surgeons during challenging or prolonged medical procedures.

To validate these advancements, a fleet of Luminus devices will be manufactured to engage in medical procedure labs, where top surgeons will finalize our user friendly training protocols.
Our commitment to innovation extends beyond the laboratory: As in our past medical labs, we will prove these breakthroughs and disseminate our findings in key industry journals. Examples include achieving complete diagnostics within joints and sinuses, coupled with the ability to consistently target medication and regenerative injections.

As we progress with medical validations, we are diligently working with our manufacturer and regulatory firms to prepare and file for FDA clearance. All LuminusMicro departments and vendors have been instructed to adhere strictly to FDA submission protocols. Our regulatory management firms are primed to coordinate and execute this process, leveraging their expertise in securing rapid clearances for market-leading products in the surgical fields we are targeting. Reports indicate that each of their “predicate” devices, substantially equivalent to Luminus by FDA standards, received their respective 510K clearances in under 35 days. These reports serve as a definitive roadmap to achieving swift clearance for LuminusMicro devices.